Wockhardt’s UK Business Continues To Grow
As Company Records Double-Digit Growth In India Market
Wockhardt’s UK segment continues to grow as the company records a 66% increase for the second quarter ending 30 September 2021. The company’s India market and Irish market performed well, while its emerging markets and US market failed to deliver.
You may also be interested in...
India’s Wockhardt has announced a fresh collaboration with the Serum Institute of India that will see the firm create a new sterile fill-and-finish facility in the UK, as part of plans to deliver an additional 150 million vaccine doses.
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
Financially stretched Wockhardt sells select branded generic business to Dr Reddy’s for $260m, bringing the curtains down on a much anticipated transaction.